Dr. Leonardi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1034 S Brentwood Blvd
Suite 600
Saint Louis, MO 63117Phone+1 314-721-5565Fax+1 314-721-6122
Education & Training
University of Miami/Jackson Health SystemResidency, Dermatology, 1986 - 1989- University of Miami/Jackson Health SystemInternship, Transitional Year, 1985 - 1986
University of Miami Leonard M. Miller School of MedicineClass of 1985
Certifications & Licensure
MO State Medical License 1992 - 2024
IL State Medical License 1996 - 2005
FL State Medical License 1989 - 1998- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Cutivate Lotion HPA Axis Pediatric Study Start of enrollment: 2007 Jul 01
- Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Start of enrollment: 2014 Jun 16
Publications & Presentations
PubMed
- 8 citationsTildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.A P Fernandez, E Dauden, S Gerdes, M G Lebwohl, M A Menter
Journal of the European Academy of Dermatology and Venereology. 2022-10-01 - Wolf's isotopic response of lichen planus following contact dermatitis.Bruin Pollard, William H McCoy 4th, Craig L Leonardi, Ann G Martin
JAAD Case Reports. 2022-09-01 - 28 citationsEfficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.April Armstrong, Kyle Fahrbach, Craig Leonardi, Matthias Augustin, Binod Neupane
Dermatology and Therapy. 2022-08-01
Journal Articles
- Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque PsoriasisAndrew Blauvelt, Craig L Leonardi, Jashin J Wu, JAMA Dermatology
Authored Content
- Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque PsoriasisApril 2020
Press Mentions
Brodalumab: 4-Year US Pharmacovigilance ReportMarch 14th, 2023
Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDJune 12th, 2019
Ixekizumab Psoriasis Outcomes, Sliced and DicedFebruary 23rd, 2019- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
